{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:20:23Z","timestamp":1788254423642,"version":"build-2803163510"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03500-9","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:59:27Z","timestamp":1788209967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-Omics-Driven Insights into Cancer Biology and Therapeutic Targeting"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8876-5529","authenticated-orcid":false,"given":"Deval","family":"Koshti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-3595","authenticated-orcid":false,"given":"Nikhil","family":"Khandale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-4300","authenticated-orcid":false,"given":"Jignesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-2240","authenticated-orcid":false,"given":"Darshil","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7072-5910","authenticated-orcid":false,"given":"Vrashabh V.","family":"Sugandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-3189","authenticated-orcid":false,"given":"Dilip","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9601-8909","authenticated-orcid":false,"given":"Vishal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0688-9563","authenticated-orcid":false,"given":"Sanyog","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"4","key":"3500_CR1","first-page":"1063","volume":"10","author":"D Pk","year":"2025","unstructured":"Pk D. Rathod VS, Rathod RD, Rathod R, Rathod RS, Koli KN. A Review on Role of Ayurveda in Modern Drug Discovery\u202f: Bridging Traditional Wisdom with Scientific Innovation. 2025;10(4):1063\u20138.","journal-title":"A Review on Role of Ayurveda in Modern Drug Discovery : Bridging Traditional Wisdom with Scientific Innovation"},{"key":"3500_CR2","volume-title":"Medicinal Plants in Ayurveda and Unani systems including Siddha in the Indian scenario","author":"I Lepcha","year":"2023","unstructured":"Lepcha I, Patra B, Saha D. Medicinal Plants in Ayurveda and Unani systems including Siddha in the Indian scenario. Shashwat publication; 2023."},{"key":"3500_CR3","doi-asserted-by":"crossref","unstructured":"Jackson DB, Racz R, Kim S, Brock S, Burkhart K. Rewiring drug research and development through human data-driven discovery (HD3). Pharmaceutics [Internet]. 2023;15(6):1673. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10303279\/. Accessed 13 Dec 2025.","DOI":"10.3390\/pharmaceutics15061673"},{"key":"3500_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jconrel.2022.03.023","volume":"345","author":"LSJ Roope","year":"2022","unstructured":"Roope LSJ. The economic challenges of new drug development. J Control Release. 2022;345:275\u20137.","journal-title":"J Control Release"},{"key":"3500_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.18632\/oncotarget.28552","volume":"15","author":"U Saqib","year":"2024","unstructured":"Saqib U, Demaree IS, Obukhov AG, Baig MS, Ariel A, Hajela K. The fate of drug discovery in academia; dumping in the publication landfill? Oncotarget. 2024;15:31.","journal-title":"Oncotarget"},{"key":"3500_CR6","doi-asserted-by":"crossref","unstructured":"Sharma A, Debik J, Naume B, Ohnstad HO, Sahlber KK, Borgen E, et al. Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes. Oncogenesis [Internet]. 2024;13(1):1\u201313. https:\/\/www.nature.com\/articles\/s41389-024-00521-6. Accessed 22 Oct 2025.","DOI":"10.1038\/s41389-024-00521-6"},{"key":"3500_CR7","doi-asserted-by":"crossref","unstructured":"Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun [Internet]. 2021;12(1):1\u201318. https:\/\/www.nature.com\/articles\/s41467-021-26502-6. Accessed 22 Oct 2025.","DOI":"10.1038\/s41467-021-26502-6"},{"key":"3500_CR8","doi-asserted-by":"crossref","unstructured":"Fan Y, Kao C, Yang F, Wang F, Yin G, Wang Y, et al. Integrated multi-omics analysis model to identify biomarkers associated with prognosis of breast cancer. Front Oncol [Internet]. 2022;12:899900. www.frontiersin.org. Accessed 22 Oct 2025.","DOI":"10.3389\/fonc.2022.899900"},{"issue":"11","key":"3500_CR9","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/s12276-024-01332-w","volume":"56","author":"KA Yoon","year":"2024","unstructured":"Yoon KA, Kim Y, Jung SY, Ryu JS, Kim KH, Lee EG, et al. Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance. Exp Mol Med. 2024;56(11):2382\u201394.","journal-title":"Exp Mol Med"},{"issue":"7894","key":"3500_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","volume":"601","author":"SJ Sammut","year":"2022","unstructured":"Sammut SJ, Crispin-Ortuzar M, Chin SF, Provenzano E, Bardwell HA, Ma W, et al. Multi-omic machine learning predictor of breast cancer therapy response. Nature. 2022;601(7894):623\u20139.","journal-title":"Nature"},{"key":"3500_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110682","author":"H Song","year":"2024","unstructured":"Song H, Tang X, Liu M, Wang G, Yuan Y, Pang R, et al. Multi-omic analysis identifies metabolic biomarkers for the early detection of breast cancer and therapeutic response prediction. iScience. 2024. https:\/\/doi.org\/10.1016\/j.isci.2024.110682.","journal-title":"iScience"},{"issue":"7","key":"3500_CR12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/metabo14070396","volume":"14","author":"BA Bauer","year":"2024","unstructured":"Bauer BA, Schmidt CM, Ruddy KJ, Olson JE, Meydan C, Schmidt JC, et al. A Multiomics, Molecular Atlas of Breast Cancer Survivors. Metabolites. 2024;14(7):396.","journal-title":"Metabolites"},{"issue":"1","key":"3500_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13073-023-01201-7","volume":"15","author":"YH Park","year":"2023","unstructured":"Park YH, Im SA, Park K, Wen J, Lee KH, Choi YL, et al. Longitudinal multi-omics study of palbociclib resistance in HR-positive\/HER2-negative metastatic breast cancer. Genome Med. 2023;15(1):55.","journal-title":"Genome Med"},{"key":"3500_CR14","doi-asserted-by":"publisher","first-page":"1580622","DOI":"10.3389\/fmolb.2025.1580622","volume":"12","author":"Q Wu","year":"2025","unstructured":"Wu Q, Cao H, Jin J, Ma D, Niu Y, Yu Y, et al. Integrated multi-omics analysis reveals the functional and prognostic significance of lactylation-related gene PRDX1 in breast cancer. Front Mol Biosci. 2025;12:1580622.","journal-title":"Front Mol Biosci"},{"key":"3500_CR15","doi-asserted-by":"publisher","unstructured":"Omran MM, Emam M, Gamaleldin M, Abushady AM, Elattar MA, El-Hadidi M. Comparative analysis of statistical and deep learning-based multi-omics integration for breast cancer subtype classification. J Transl Med. 2025;23(1):709. https:\/\/doi.org\/10.1186\/s12967-025-06662-5.","DOI":"10.1186\/s12967-025-06662-5"},{"key":"3500_CR16","doi-asserted-by":"crossref","unstructured":"Song KJ, Choi S, Kim K, Hwang HS, Chang E, Park JS, et al. Proteogenomic analysis reveals non-small cell lung cancer subtypes predicting chromosome instability, and tumor microenvironment. Nat Commun [Internet]. 2024;15(1):1\u201325. https:\/\/www.nature.com\/articles\/s41467-024-54434-4. Accessed 22 Oct 2025.","DOI":"10.1038\/s41467-024-54434-4"},{"key":"3500_CR17","unstructured":"Satpathy S, Clark NM, Chen YJ, Hosseini N, Chang YH, Hsiao Y, et al. Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures. Cancer Cell [Internet]. 2025;43(9):1731\u20131757.e17. https:\/\/www.cell.com\/action\/showFullText?pii=S1535610825003174. Accessed 22 Oct 2025."},{"key":"3500_CR18","unstructured":"Roh W, Geffen Y, Cha H, Miller M, Anand S, Kim J, Heiman DI, Gainor JF, Laird PW, Cherniack AD, Ock CY. High-resolution profiling of lung adenocarcinoma identifies expression subtypes with specific biomarkers and clinically relevant vulnerabilities. Cancer Res. 2022;82(21):3917\u201331. https:\/\/aacrjournals.org\/cancerres\/article-abstract\/82\/21\/3917\/709962\/High-Resolution-Profiling-of-Lung-Adenocarcinoma."},{"key":"3500_CR19","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wang Y, Qian H. Multi-omics characterization and machine learning of lung adenocarcinoma molecular subtypes to guide precise chemotherapy and immunotherapy. Front Immunol [Internet]. 2024;15:1497300. https:\/\/portal.gdc.cancer.gov. Accessed 22 Oct 2025.","DOI":"10.3389\/fimmu.2024.1497300"},{"key":"3500_CR20","doi-asserted-by":"crossref","unstructured":"Wu S, Pan J, Pan Q, Zeng L, Liang R, Li Y. Multi-omics profiling and experimental verification of tertiary lymphoid structure-related genes: molecular subgroups, immune infiltration, and prognostic implications in lung adenocarcinoma. Front Immunol [Internet]. 2024;15:1453220. https:\/\/portal.gdc.cancer.gov\/. Accessed 22 Oct 2025.","DOI":"10.3389\/fimmu.2024.1453220"},{"key":"3500_CR21","doi-asserted-by":"crossref","unstructured":"Chen Z, Mei K, Tan F, Zhou Y, Du H, Wang M, et al. Integrative multi-omics analysis for identifying novel therapeutic targets and predicting immunotherapy efficacy in lung adenocarcinoma. Cancer Drug Resist [Internet]. 2025;8:3. https:\/\/www.oaepublish.com\/articles\/cdr.2024.91. Accessed 22 Oct 2025.","DOI":"10.20517\/cdr.2024.91"},{"key":"3500_CR22","doi-asserted-by":"crossref","unstructured":"Wang N, Li Y, Wang Y, Wang W. Integration of multi-omics profiling reveals an epigenetic-based molecular classification of lung adenocarcinoma: implications for drug sensitivity and immunotherapy response prediction. Front Pharmacol [Internet]. 2025;16:1540477. https:\/\/portal.gdc.cancer. Accessed 22 Oct 2025.","DOI":"10.3389\/fphar.2025.1540477"},{"key":"3500_CR23","doi-asserted-by":"crossref","unstructured":"Chen Y, Li E, Chang Z, Zhang T, Song Z, Wu H, et al. Identifying potential therapeutic targets in lung adenocarcinoma: a multi-omics approach integrating bulk and single-cell RNA sequencing with Mendelian randomization. Front Pharmacol [Internet]. 2024;15:1433147. https:\/\/gtexportal.org\/home\/datasets\/. Accessed 22 Oct 2025.","DOI":"10.3389\/fphar.2024.1433147"},{"key":"3500_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1479550","volume":"16","author":"R Wu","year":"2025","unstructured":"Wu R, Wei K, Huang X, Zhou Y, Feng X, Dong X, et al. Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer. Front Immunol. 2025;16:1479550.","journal-title":"Front Immunol"},{"key":"3500_CR25","doi-asserted-by":"crossref","unstructured":"Zhang J, Zhou W, Li N, Li H, Luo H, Jiang B. Multi-omics analysis unveils immunosuppressive microenvironment in the occurrence and development of multiple pulmonary lung cancers. npj Precis Oncol [Internet]. 2024 Dec 1 [cited 2025 Oct 22];8(1):1\u201312. Available from: https:\/\/www.nature.com\/articles\/s41698-024-00651-5","DOI":"10.1038\/s41698-024-00651-5"},{"key":"3500_CR26","doi-asserted-by":"crossref","unstructured":"Zhao M, Xue G, He B, Deng J, Wang T, Zhong Y, et al. Integrated multiomics signatures to optimize the accurate diagnosis of lung cancer. Nat Commun [Internet]. 2025 Dec 1 [cited 2025 Oct 22];16(1):1\u201316. Available from: https:\/\/www.nature.com\/articles\/s41467-024-55594-z","DOI":"10.1038\/s41467-024-55594-z"},{"key":"3500_CR27","doi-asserted-by":"crossref","unstructured":"Tran TO, Vo TH, Lam LHT, Le NQK. ALDH2 as a potential stem cell-related biomarker in lung adenocarcinoma: Comprehensive multi-omics analysis. Comput Struct Biotechnol J [Internet]. 2023 Jan 1 [cited 2025 Oct 22];21:1921\u20139. Available from: https:\/\/www.csbj.org\/action\/showFullText?pii=S2001037023000910","DOI":"10.1016\/j.csbj.2023.02.045"},{"issue":"7","key":"3500_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11071861","volume":"11","author":"L Wu","year":"2023","unstructured":"Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, et al. Multiple omics analysis of the role of RBM10 gene instability in immune regulation and drug sensitivity in patients with lung adenocarcinoma (LUAD). Biomedicines. 2023;11(7):1861.","journal-title":"Biomedicines"},{"key":"3500_CR29","doi-asserted-by":"crossref","unstructured":"Afenteva D, Yu R, Rajavuori A, Salvadores M, Launonen IM, Lavikka K, et al. Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer. Cell Reports Med [Internet]. 2025;6(9):102316. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666379125003891?via%3Dihub. Accessed 22 Oct 2025.","DOI":"10.1016\/j.xcrm.2025.102316"},{"key":"3500_CR30","doi-asserted-by":"publisher","unstructured":"Wang J, Song G, Xing L. Multi-Omics analysis and in vitro validation reveal diagnostic and therapeutic roles of novel hub genes in ovarian cancer. Hereditas [Internet]. 2025;162(1):1\u201318. https:\/\/doi.org\/10.1186\/s41065-025-00535-z.","DOI":"10.1186\/s41065-025-00535-z"},{"key":"3500_CR31","doi-asserted-by":"publisher","unstructured":"Ye L, Long C, Xu B, Yao X, Yu J, Luo Y, et al. Multi\u2011omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study. Mol Med [Internet]. 2025;31(1):1\u201329. https:\/\/doi.org\/10.1186\/s10020-024-01036-x.","DOI":"10.1186\/s10020-024-01036-x"},{"key":"3500_CR32","doi-asserted-by":"crossref","unstructured":"Wang Z, Li Y, Zhao W, Jiang S, Huang Y, Hou J, et al. Integrative multi-omics and drug\u2013response characterization of patient-derived prostate cancer primary cells. Signal Transduct Target Ther [Internet]. 2023;8(1):1\u201316. https:\/\/www.nature.com\/articles\/s41392-023-01393-9. Accessed 22 Oct 2025.","DOI":"10.1038\/s41392-023-01393-9"},{"key":"3500_CR33","doi-asserted-by":"crossref","unstructured":"Villa M, Cazzaniga G, Bolognesi M, Malighetti F, Crippa V, Aroldi A, Bozzini G, Pagni F, Piazza R, Mologni L, Ramazzotti D. Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers. Heliyon. 2025;11(12). https:\/\/www.cell.com\/heliyon\/fulltext\/S2405-8440(25)01919-X.","DOI":"10.1016\/j.heliyon.2025.e43533"},{"key":"3500_CR34","doi-asserted-by":"crossref","unstructured":"Liu X, Yu W, Jin X, Wang Y, Liu K. Multi-omics evaluation of cell lines as models for metastatic prostate cancer. Commun Biol. 2026. https:\/\/www.nature.com\/articles\/s42003-026-09914-2.","DOI":"10.1101\/2025.07.17.665334"},{"key":"3500_CR35","doi-asserted-by":"crossref","unstructured":"Zhu W, Wu J, Huang J, Xiao D, Li F, Wu C, Li X, Zeng H, Zheng J, Lai W, Wen X. Multi-omics analysis reveals a macrophage-related marker gene signature for prognostic prediction, immune landscape, genomic heterogeneity, and drug choices in prostate cancer. Front Immunol. 2023;14:1122670.\u00a0https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2023.1122670\/full.","DOI":"10.3389\/fimmu.2023.1122670"},{"key":"3500_CR36","doi-asserted-by":"crossref","unstructured":"Fan X, He Z, Guo J, Bu D, Han D, Qu X, Li Q, Cheng S, Han A, Guo J. Leveraging TME features and multi-omics data with an advanced deep learning framework for improved Cancer survival prediction. Sci Rep. 2025;15(1):14282. https:\/\/www.nature.com\/articles\/s41598-025-98565-0.","DOI":"10.1038\/s41598-025-98565-0"},{"key":"3500_CR37","doi-asserted-by":"publisher","unstructured":"Yang Y, Liu Z, Wei Y, He S, Gu A, Li Z, et al. Single-cell multi-omics analysis reveals candidate therapeutic drugs and key transcription factor specifically for the mesenchymal subtype of glioblastoma. Cell Biosci [Internet]. 2024;14(1):1\u201321. https:\/\/doi.org\/10.1186\/s13578-024-01332-3.","DOI":"10.1186\/s13578-024-01332-3"},{"key":"3500_CR38","doi-asserted-by":"publisher","unstructured":"Wang X, Sun Q, Liu T, Lu H, Lin X, Wang W, et al. Single-cell multi-omics sequencing uncovers region-specific plasticity of glioblastoma for complementary therapeutic targeting. Sci Adv [Internet]. 2024 Nov 22 [cited 2025 Oct 22];10(47):4306. Available from: \/doi\/pdf\/https:\/\/doi.org\/10.1126\/sciadv.adn4306?download=true","DOI":"10.1126\/sciadv.adn4306?download=true"},{"key":"3500_CR39","doi-asserted-by":"publisher","unstructured":"Wang F, Chen Y, Huang R, Lu D, Zhang J, Yang Y, et al. Identification of SURF4 and RALGAPA1 as promising therapeutic targets in glioblastoma and pan-cancer through integrative multi-omics, CRISPR-Cas9 screening and prognostic meta-analysis. Cancer Immunol Immunother [Internet]. 2025;74(6):1\u201318. https:\/\/doi.org\/10.1007\/s00262-025-04034-y.","DOI":"10.1007\/s00262-025-04034-y"},{"key":"3500_CR40","doi-asserted-by":"crossref","unstructured":"Zhu J, Kong W, Huang L, Bi S, Jiao X, Zhu S. Identification of immunotherapy and chemotherapy-related molecular subtypes in colon cancer by integrated multi-omics data analysis. Front Immunol [Internet]. 2023;14:1142609. https:\/\/portal.gdc.cancer.gov\/. Accessed 22 Oct 2025.","DOI":"10.3389\/fimmu.2023.1142609"},{"key":"3500_CR41","doi-asserted-by":"crossref","unstructured":"Xu T, Ngan DK, Zheng W, Huang R. Systematic identification of cancer pathways and potential drugs for intervention through multi-omics analysis. Pharmacogenomics J [Internet]. 2025 Apr 1 [cited 2025 Oct 22];25(2):1\u20139. Available from: https:\/\/www.nature.com\/articles\/s41397-025-00361-6","DOI":"10.1038\/s41397-025-00361-6"},{"key":"3500_CR42","doi-asserted-by":"crossref","unstructured":"Du M, Gu D, Xin J, Peters U, Song M, Cai G, Li S, Ben S, Meng Y, Chu H, Chen L. Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer. Cell Rep Med. 2023;4(3). https:\/\/www.cell.com\/cell-reports-medicine\/fulltext\/S2666-3791(23)00080-0.","DOI":"10.1016\/j.xcrm.2023.100974"},{"key":"3500_CR43","doi-asserted-by":"crossref","unstructured":"Zafari N, Bathaei P, Velayati M, Khojasteh-Leylakoohi F, Khazaei M, Fiuji H, et al. Integrated analysis of multi-omics data for the discovery of biomarkers and therapeutic targets for colorectal cancer. Comput Biol Med [Internet]. 2023 Mar 1 [cited 2025 Oct 22];155:106639. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S001048252300104X?via%3Dihub","DOI":"10.1016\/j.compbiomed.2023.106639"},{"key":"3500_CR44","doi-asserted-by":"crossref","unstructured":"Buttacavoli M, Di Cara G, Roz E, Pucci-Minafra I, Feo S, Cancemi P. Integrated multi-omics investigations of metalloproteinases in colon cancer: Focus on mmp2 and mmp9. Int J Mol Sci [Internet]. 2021 Nov 1 [cited 2025 Oct 22];22(22):12389. Available from: https:\/\/www.mdpi.com\/1422-0067\/22\/22\/12389\/htm","DOI":"10.3390\/ijms222212389"},{"key":"3500_CR45","unstructured":"Study Details | NCT04525807 | Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04525807"},{"key":"3500_CR46","unstructured":"Study Details | NCT05794841 | Multi-omics Study of Tongue Coating in Malignant Tumors of Digestive Tract | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05794841"},{"key":"3500_CR47","unstructured":"Study Details | NCT04947995 | Multi-Omics Noninvasive Inspection of TumOr Risk for Gastric Cancer | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04947995"},{"key":"3500_CR48","unstructured":"Study Details | NCT06456281 | Multi-omics Model for Pancreatic Cancer Screening Using cfDNA | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06456281"},{"key":"3500_CR49","unstructured":"Study Details | NCT04931446 | Neuroendocrine neoplasm based on multi-omics integrated analysis. ClinicalTrials.gov [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT04931446. Accessed 7 Mar 2026."},{"key":"3500_CR50","unstructured":"Study Details | NCT05985941 | Prospective multi-omics observational study of gynecological rare pathological tumors. ClinicalTrials.gov [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT05985941. Accessed 7 Mar 2026."},{"key":"3500_CR51","unstructured":"Study Details | NCT05812287 | Exploring the difference between gastric cardia cancer and non-cardia gastric cancer based on multiomics. ClinicalTrials.gov [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT05812287. Accessed 7 Mar 2026."},{"key":"3500_CR52","unstructured":"Study Details | NCT07445438 | Feasibility of a Multi-omics Platform for Hematological Malignancies | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07445438"},{"key":"3500_CR53","unstructured":"Study Details | NCT07403630 | INTEGRATIVE \u201cMULTI-OMICS\u201d AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP) | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07403630"},{"key":"3500_CR54","unstructured":"Study Details | NCT07351266 | | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07351266"},{"key":"3500_CR55","unstructured":"Study Details | NCT07131007 | Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07131007"},{"key":"3500_CR56","unstructured":"Study Details | NCT06699979 | Multi-omics Study of Early-stage Lung Cancer with Distinct Phenotypes | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06699979"},{"key":"3500_CR57","unstructured":"Study Details | NCT07448376 | EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07448376"},{"key":"3500_CR58","unstructured":"Study Details | NCT07101237 | An exploratory study on developing an integrated approach combining multimodal imaging and multi-omics characterization of tumor heterogeneity for precision diagnosis and treatment optimization in liver cancer. ClinicalTrials.gov [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT07101237. Accessed 7 Mar 2026."},{"key":"3500_CR59","unstructured":"Study Details | NCT06833723 | Development of a Multi-omics Prediction Model for Immunotherapy Response in Triple-Negative Breast Cancer Subtypes | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06833723"},{"key":"3500_CR60","unstructured":"Study Details | NCT07007689 | A multi-omics study of braf v600e mutant colorectal cancer. ClinicalTrials.gov [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT07007689. Accessed 7 Mar 2026."},{"key":"3500_CR61","unstructured":"Study Details | NCT05974475 | MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05974475"},{"key":"3500_CR62","unstructured":"Study Details | NCT05368051 | Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05368051"},{"key":"3500_CR63","unstructured":"Study Details | NCT07190040 | Integrating Multi-Omics Data for Enhanced Prognosis Prediction in Gastric Cancer Post-Neoadjuvant Therapy | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07190040"},{"key":"3500_CR64","unstructured":"Study Details | NCT06220617 | Multi-omics study for early detection of colorectal cancer (MOED-CRC). ClinicalTrials.gov [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT06220617. Accessed 7 Mar 2026."},{"key":"3500_CR65","unstructured":"Study Details | NCT05928299 | Integrative multi-omics testing for immunotherapy response in non-small cell lung cancer. ClinicalTrials.gov [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT05928299. Accessed 7 Mar 2026."},{"key":"3500_CR66","unstructured":"Study Details | NCT06524245 | A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood | ClinicalTrials.gov [Internet]. [cited 2026 Mar 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06524245"},{"key":"3500_CR67","doi-asserted-by":"crossref","unstructured":"Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, Mercola M. Phenotypic Drug Discovery: Recent successes, lessons learned and new directions. Nat Rev Drug Discov [Internet]. 2022 Dec 1 [cited 2025 Dec 13];21(12):899. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9708951\/","DOI":"10.1038\/s41573-022-00472-w"},{"key":"3500_CR68","doi-asserted-by":"crossref","unstructured":"Xu J, Li X, Jia Y. Target screening and optimization of candidate compounds for breast cancer treatment using bioinformatics and computational chemistry approaches. Front Pharmacol [Internet]. 2025 May 9 [cited 2025 Dec 13];16:1467504. Available from: http:\/\/swisstargetprediction.ch","DOI":"10.3389\/fphar.2025.1467504"},{"key":"3500_CR69","doi-asserted-by":"crossref","unstructured":"Oliveira TA de, Silva MP da, Maia EHB, Silva AM da, Taranto AG. Virtual Screening Algorithms in Drug Discovery: A Review Focused on Machine and Deep Learning Methods. Drugs Drug Candidates 2023, Vol 2, Pages 311\u2013334 [Internet]. 2023 May 5 [cited 2025 Dec 13];2(2):311\u201334. Available from: https:\/\/www.mdpi.com\/2813-2998\/2\/2\/17\/htm","DOI":"10.3390\/ddc2020017"},{"key":"3500_CR70","doi-asserted-by":"crossref","unstructured":"Gao Q, Wu H, Duan L, Lv G, Quan D. Multi-omics analysis of the tumor microenvironment after metastasis: advancing toward personalized immunotherapy and molecular targeted strategies. Front Immunol. 2025;16:1648987.\u00a0https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2025.1648987\/full","DOI":"10.3389\/fimmu.2025.1648987"},{"key":"3500_CR71","doi-asserted-by":"crossref","unstructured":"Mohammadi-Shemirani P, Sood T, Par\u00e9 G. From \u2018Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators. Curr Atheroscler Rep [Internet]. 2023 Feb 1 [cited 2025 Dec 13];25(2):55. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9807989\/","DOI":"10.1007\/s11883-022-01078-8"},{"key":"3500_CR72","doi-asserted-by":"crossref","unstructured":"Luo Y, Zhao C, Chen F. Multiomics Research: Principles and Challenges in Integrated Analysis. Biodesign Res [Internet]. 2024 [cited 2025 Dec 13];6:0059. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11844812\/","DOI":"10.34133\/bdr.0059"},{"issue":"4","key":"3500_CR73","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/proteomes11040034","volume":"11","author":"T Ivanisevic","year":"2023","unstructured":"Ivanisevic T, Sewduth RN. Multi-omics integration for the design of novel therapies and the identification of novel biomarkers. Proteomes. 2023;11(4):34.","journal-title":"Proteomes"},{"key":"3500_CR74","doi-asserted-by":"crossref","unstructured":"Ye Q, Guo NL. Inferencing bulk tumor and single-cell multi-omics regulatory networks for discovery of biomarkers and therapeutic targets. Cells [Internet]. 2022;12(1):101. https:\/\/www.mdpi.com\/2073-4409\/12\/1\/101\/htm. Accessed 13 Dec 2025.","DOI":"10.3390\/cells12010101"},{"key":"3500_CR75","doi-asserted-by":"crossref","unstructured":"Ivanisevic T, Sewduth RN. Multi-omics integration for the design of novel therapies and the identification of novel biomarkers. Proteomes [Internet]. 2023;11(4):34.\u00a0https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10594525\/. Accessed 22 Oct 2025.","DOI":"10.3390\/proteomes11040034"},{"key":"3500_CR76","doi-asserted-by":"crossref","unstructured":"Reel PS, Reel S, Pearson E, Trucco E, Jefferson E. Using machine learning approaches for multi-omics data analysis: a review. Biotechnol Adv [Internet]. 2021;49:107739. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0734975021000458. Accessed 14 Feb 2026.","DOI":"10.1016\/j.biotechadv.2021.107739"},{"key":"3500_CR77","doi-asserted-by":"crossref","unstructured":"Li Y, Ma L, Wu D, Chen G. Advances in bulk and single-cell multi-omics approaches for systems biology and precision medicine. Brief Bioinform. 2021;22(5):bbab024.","DOI":"10.1093\/bib\/bbab024"},{"key":"3500_CR78","doi-asserted-by":"crossref","unstructured":"Thomas JP, Modos D, Korcsmaros T, Brooks-Warburton J. Network biology approaches to achieve precision medicine in inflammatory bowel disease. Front Genet. 2021;12:760501.","DOI":"10.3389\/fgene.2021.760501"},{"key":"3500_CR79","doi-asserted-by":"crossref","unstructured":"Maayan Baron et al. Use of a systems-biology informed machine learning model to predict drug response using clinically available NGS data.. J Clin Oncol 41, 3136-3136(2023). DOI:10.1200\/JCO.2023.41.16_suppl.3136 https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.3136","DOI":"10.1200\/JCO.2023.41.16_suppl.3136"},{"key":"3500_CR80","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biodatasci-102523-103801","author":"Y Nam","year":"2024","unstructured":"Nam Y, Kim J, Jung SH, Woerner J, Suh EH, Lee D, et al. Harnessing artificial intelligence in multimodal omics data integration: paving the path for the next frontier in precision medicine. Annu Rev Biomed Data Sci. 2024. https:\/\/doi.org\/10.1146\/annurev-biodatasci-102523-103801.","journal-title":"Annu Rev Biomed Data Sci"},{"key":"3500_CR81","doi-asserted-by":"crossref","unstructured":"Krassowski M, Das V, Sahu SK, Misra BB. State of the field in multi-omics research: from computational needs to data mining and sharing. Front Genet [Internet]. 2020;11:610798. www.frontiersin.org. Accessed 2 Jun 2026.","DOI":"10.3389\/fgene.2020.610798"},{"key":"3500_CR82","doi-asserted-by":"crossref","unstructured":"Picard M, Scott-Boyer MP, Bodein A, P\u00e9rin O, Droit A. Integration strategies of multi-omics data for machine learning analysis. Comput Struct Biotechnol J [Internet]. 2021;19:3735\u201346. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2001037021002683. Accessed 3 Jun 2026.","DOI":"10.1016\/j.csbj.2021.06.030"},{"key":"3500_CR83","unstructured":"Rajendran DOK. Foundation model\u2013driven precision oncology: integrating multi-omics, radiology, and clinical data for predictive cancer care. Power Syst Prot Control [Internet]. 2024;52(2):154\u201363. https:\/\/pspac.info\/index.php\/dlbh\/article\/view\/324. Accessed 3 Jun 2026."},{"key":"3500_CR84","unstructured":"Sada K, Real D, Rubio Diaz-Cordov\u00e9s A. Application of explainable artificial intelligence to precision oncology. 2025. https:\/\/hdl.handle.net\/10171\/117527. Accessed 3 Jun 2026."},{"key":"3500_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2022.100190","author":"S Namba","year":"2022","unstructured":"Namba S, Konuma T, Wu KH, Zhou W, Okada Y. A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. Cell Genom. 2022. https:\/\/doi.org\/10.1016\/j.xgen.2022.100190.","journal-title":"Cell Genom"},{"issue":"3","key":"3500_CR86","doi-asserted-by":"publisher","first-page":"107","DOI":"10.30574\/wjbphs.2024.17.3.0116","volume":"17","author":"N Keerthana","year":"2024","unstructured":"Keerthana N, Koteeswaran K. Target identification and validation in research. World J Biol Pharm Heal Sci. 2024;17(3):107\u201317.","journal-title":"World J Biol Pharm Heal Sci"},{"issue":"7","key":"3500_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272129","volume":"17","author":"S Lee","year":"2022","unstructured":"Lee S, Shin JY, Kwon NJ, Kim C, Seo JS. ClinPharmSeq: a targeted sequencing panel for clinical pharmacogenetics implementation. PLoS ONE. 2022;17(7):e0272129.","journal-title":"PLoS ONE"},{"issue":"2","key":"3500_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.481","volume":"5","author":"X Zhang","year":"2024","unstructured":"Zhang X, Yu W, Li Y, Wang A, Cao H, Fu Y. Drug development advances in human genetics-based targets. MedComm. 2024;5(2):e481.","journal-title":"MedComm"},{"key":"3500_CR89","doi-asserted-by":"publisher","unstructured":"Liu J, Qing T, he M, Xu L, Wu Z, Huang M, et al. Transcriptomics, single-cell sequencing and spatial sequencing-based studies of cerebral ischemia. Eur J Med Res 2025 301 [Internet]. 2025;30(1):326. https:\/\/doi.org\/10.1186\/s40001-025-02596-2.","DOI":"10.1186\/s40001-025-02596-2"},{"key":"3500_CR90","doi-asserted-by":"crossref","unstructured":"Zhang L, Chen D, Song D, Liu X, Zhang Y, Xu X, et al. Clinical and translational values of spatial transcriptomics. Signal Transduct Target Ther 2022 71 [Internet]. 2022;7(1):111. https:\/\/www.nature.com\/articles\/s41392-022-00960-w. Accessed 13 Dec 2025.","DOI":"10.1038\/s41392-022-00960-w"},{"key":"3500_CR91","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fgene.2020.00019","volume":"11","author":"X Yang","year":"2020","unstructured":"Yang X, Kui L, Tang M, Li D, Wei K, Chen W, et al. High-throughput transcriptome profiling in drug and biomarker discovery. Front Genet. 2020;11:19.","journal-title":"Front Genet"},{"key":"3500_CR92","doi-asserted-by":"crossref","unstructured":"Qi X, Zhao L, Tian C, Li Y, Chen ZL, Huo P, et al. Predicting transcriptional responses to novel chemical perturbations using deep generative model for drug discovery. Nat Commun 2024 151 [Internet]. 2024;15(1):9256. https:\/\/www.nature.com\/articles\/s41467-024-53457-1. Accessed 13 Dec 2025.","DOI":"10.1038\/s41467-024-53457-1"},{"key":"3500_CR93","doi-asserted-by":"crossref","unstructured":"Sab\u00f2 A, Griesmayr NF, Neumann T, Manzenreither R, Ivankovic M, Costa RPV, et al. QUANTROseq, a transcriptomic based drug discovery platform using time-resolved gene expression profiling: identification of inhibitors and degraders of transcription factors and cell signaling regulators. Cancer Res. 2024;84(6_Supplement):2067.","DOI":"10.1158\/1538-7445.AM2024-2067"},{"key":"3500_CR94","doi-asserted-by":"crossref","unstructured":"Trachet EE, Holmquist C, Nagl S, Gonzales PM. Advancing precision oncology: development and utilization of breast cancer PDX models for in vivo drug discovery. Cancer Res. 2025;85(8_Supplement_1):1273.","DOI":"10.1158\/1538-7445.AM2025-1273"},{"key":"3500_CR95","doi-asserted-by":"crossref","unstructured":"Elango R, Rashid S, Vishnubalaji R, Al-sarraf R, Akhtar M, Ouararhni K. Transcriptome profiling and network enrichment analyses identify subtype-specific therapeutic gene targets for breast cancer and their microRNA regulatory networks. 2023;(January):1\u201314.","DOI":"10.1038\/s41419-023-05908-8"},{"key":"3500_CR96","unstructured":"Imam F, Saloner R, Vogel JW, Krish V, Abdel-Azim G, Ali M, et al. The global neurodegeneration proteomics consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging. Nat Med. 2025;1\u201311."},{"key":"3500_CR97","doi-asserted-by":"crossref","unstructured":"Rossi M, Radisky DC. Multiplex digital spatial profiling in breast cancer research: state-of-the-art technologies and applications across the translational science spectrum. Cancers [Internet]. 2024;16(9):1615. https:\/\/www.mdpi.com\/2072-6694\/16\/9\/1615\/htm. Accessed 3 Jun 2026.","DOI":"10.3390\/cancers16091615"},{"key":"3500_CR98","doi-asserted-by":"crossref","unstructured":"Liu F, Li G, Zheng Y, Liu Y, Liu K. Multiplex imaging analysis of the tumor immune microenvironment for guiding precision immunotherapy. Front Immunol. 2025;16:1617906.","DOI":"10.3389\/fimmu.2025.1617906"},{"key":"3500_CR99","doi-asserted-by":"publisher","unstructured":"Kim H, Hall DR, Nierves L, Lin TT, Kitata RB, Shi T, et al. The evolution of analytical techniques for multiplex analysis of protein biomarkers. Expert Rev Proteomics [Internet]. 2025;22(7):255\u201372. https:\/\/doi.org\/10.1080\/14789450.2025.2529185.","DOI":"10.1080\/14789450.2025.2529185"},{"key":"3500_CR100","doi-asserted-by":"crossref","unstructured":"Tan CW, Berrell N, Donovan ML, Monkman J, Lawler C, Sadeghirad H, et al. The development of a high-plex spatial proteomic methodology for the characterisation of the head and neck tumour microenvironment. npj Precis Oncol [Internet]. 2025;9(1):191. https:\/\/www.nature.com\/articles\/s41698-025-00963-0. Accessed 3 Jun 2026.","DOI":"10.1038\/s41698-025-00963-0"},{"issue":"5","key":"3500_CR101","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/17460441.2025.2490248","volume":"20","author":"ML Spitz","year":"2025","unstructured":"Spitz ML, Kashkush A, Benhamou RI. Advancing target validation with PROTAC technology. Expert Opin Drug Discov. 2025;20(5):551\u201363.","journal-title":"Expert Opin Drug Discov"},{"key":"3500_CR102","doi-asserted-by":"crossref","unstructured":"Ford MJ, Amunugama R, Allen DL, Jones RC. Mass spectrometry-based proteomics for accelerating PROTAC and molecular glue drug discovery. Cancer Res. 2025;85(8_Supplement_1):7027.","DOI":"10.1158\/1538-7445.AM2025-7027"},{"issue":"1","key":"3500_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.102012","volume":"4","author":"FD Johnson","year":"2023","unstructured":"Johnson FD, Hughes CS, Liu A, Lockwood WW, Morin GB. Tandem mass tag-based thermal proteome profiling for the discovery of drug-protein interactions in cancer cells. STAR Protoc. 2023;4(1):102012.","journal-title":"STAR Protoc"},{"issue":"37","key":"3500_CR104","doi-asserted-by":"publisher","first-page":"13844","DOI":"10.1021\/acs.analchem.3c01941","volume":"95","author":"X Lu","year":"2023","unstructured":"Lu X, Liao B, Sun S, Mao Y, Wu Q, Tian R, et al. Scaled-down thermal profiling and coaggregation analysis of the proteome for drug target and protein interaction analysis. Anal Chem. 2023;95(37):13844\u201354.","journal-title":"Anal Chem"},{"issue":"1","key":"3500_CR105","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12014-023-09424-x","volume":"20","author":"AG Birhanu","year":"2023","unstructured":"Birhanu AG. Mass spectrometry-based proteomics as an emerging tool in clinical laboratories. Clin Proteomics. 2023;20(1):32.","journal-title":"Clin Proteomics"},{"issue":"6","key":"3500_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100561","volume":"22","author":"M Babu","year":"2023","unstructured":"Babu M, Snyder M. Multi-omics profiling for health. Mol Cell Proteomics. 2023;22(6):100561.","journal-title":"Mol Cell Proteomics"},{"key":"3500_CR107","first-page":"427","volume":"33","author":"S Ogata","year":"2022","unstructured":"Ogata S, Masuda T, Ito S, Ohtsuki S. Targeted proteomics for cancer biomarker verification and validation. 2022;33:427\u201336.","journal-title":"Targeted proteomics for cancer biomarker verification and validation"},{"issue":"10","key":"3500_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103751","volume":"28","author":"G Astarita","year":"2023","unstructured":"Astarita G, Kelly RS, Lasky-Su J. Metabolomics and lipidomics strategies in modern drug discovery and development. Drug Discov Today. 2023;28(10):103751.","journal-title":"Drug Discov Today"},{"key":"3500_CR109","doi-asserted-by":"crossref","unstructured":"Nascentes Melo LM, Lesner NP, Sabatier M, Ubellacker JM, Tasdogan A. Emerging metabolomic tools to study cancer metastasis. Trends Cancer [Internet]. 2022;8(12):988\u20131001. https:\/\/www.cell.com\/action\/showFullText?pii=S240580332200156X. Accessed 13 Dec 2025.","DOI":"10.1016\/j.trecan.2022.07.003"},{"key":"3500_CR110","doi-asserted-by":"crossref","unstructured":"Zhang R, Chen B, Zhang H, Tu L, Luan T. Stable isotope-based metabolic flux analysis: a robust tool for revealing toxicity pathways of emerging contaminants. TrAC Trends Anal Chem [Internet]. 2023;159:116909. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0165993622003922. Accessed 13 Dec 2025.","DOI":"10.1016\/j.trac.2022.116909"},{"key":"3500_CR111","doi-asserted-by":"crossref","unstructured":"Riekeberg E, Powers R. New frontiers in metabolomics: from measurement to insight. F1000Research. 2017;6:1148.","DOI":"10.12688\/f1000research.11495.1"},{"issue":"8","key":"3500_CR112","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1016\/j.apsb.2023.05.021","volume":"13","author":"H Pang","year":"2023","unstructured":"Pang H, Hu Z. Metabolomics in drug research and development: the recent advances in technologies and applications. Acta Pharm Sin B. 2023;13(8):3238\u201351.","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"3500_CR113","doi-asserted-by":"publisher","DOI":"10.15252\/msb.202210914","volume":"18","author":"BB Garana","year":"2022","unstructured":"Garana BB, Graham NA. Metabolomics paves the way for improved drug target identification. Mol Syst Biol. 2022;18(2):e10914.","journal-title":"Mol Syst Biol"},{"issue":"11","key":"3500_CR114","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.792","volume":"5","author":"S Pan","year":"2024","unstructured":"Pan S, Yin L, Liu J, Tong J, Wang Z, Zhao J, et al. Metabolomics\u2010driven approaches for identifying therapeutic targets in drug discovery. MedComm. 2024;5(11):e792.","journal-title":"MedComm"},{"issue":"3\u20134","key":"3500_CR115","first-page":"104","volume":"4","author":"C G\u00e9hin","year":"2022","unstructured":"G\u00e9hin C, Fowler SJ, Trivedi DK. Chewing the fat: how lipidomics is changing our understanding of human health and disease in 2022. Anal Sci Adv. 2022;4(3\u20134):104\u201331.","journal-title":"Anal Sci Adv"},{"issue":"4","key":"3500_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12040333","volume":"12","author":"K Ahluwalia","year":"2022","unstructured":"Ahluwalia K, Ebright B, Chow K, Dave P, Mead A, Poblete R, et al. Lipidomics in understanding pathophysiology and pharmacologic effects in inflammatory diseases: considerations for drug development. Metabolites. 2022;12(4):333.","journal-title":"Metabolites"},{"issue":"1","key":"3500_CR117","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.1038\/s41467-023-42532-8","volume":"14","author":"L Ottensmann","year":"2023","unstructured":"Ottensmann L, Tabassum R, Ruotsalainen SE, Gerl MJ, Klose C, Wid\u00e9n E, et al. Genome-wide association analysis of plasma lipidome identifies 495 genetic associations. Nat Commun. 2023;14(1):6934.","journal-title":"Nat Commun"},{"key":"3500_CR118","doi-asserted-by":"publisher","unstructured":"Nishimoto K, Okahashi N, Maruyama M, Izumi Y, Nakatani K, Ito Y, et al. Lipidome and metabolome analyses reveal metabolic alterations associated with MCF \u2011 7 apoptosis upon 4 \u2011 hydroxytamoxifen treatment. Sci Rep [Internet]. 2023;1\u201310. https:\/\/doi.org\/10.1038\/s41598-023-45764-2.","DOI":"10.1038\/s41598-023-45764-2"},{"issue":"1","key":"3500_CR119","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13148-022-01419-z","volume":"15","author":"T Feehley","year":"2023","unstructured":"Feehley T, O\u2019Donnell CW, Mendlein J, Karande M, McCauley T. Drugging the epigenome in the age of precision medicine. Clin Epigenetics. 2023;15(1):6. https:\/\/doi.org\/10.1186\/s13148-022-01419-z","journal-title":"Clin Epigenetics"},{"key":"3500_CR120","doi-asserted-by":"crossref","unstructured":"Sadida HQ, Abdulla A, Marzooqi S Al, Hashem S, Macha MA, Akil ASAS, et al. Epigenetic modifications: key players in cancer heterogeneity and drug resistance. Transl Oncol [Internet]. 2023;39:101821. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10654239\/. Accessed 13 Dec 2025.","DOI":"10.1016\/j.tranon.2023.101821"},{"key":"3500_CR121","doi-asserted-by":"publisher","DOI":"10.1017\/pcm.2023.6","volume":"1","author":"DA Smith","year":"2023","unstructured":"Smith DA, Sadler MC, Altman RB. Promises and challenges in pharmacoepigenetics. Cambridge Prism Precis Med. 2023;1:e18.","journal-title":"Cambridge Prism Precis Med"},{"key":"3500_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1465954","volume":"15","author":"S Li","year":"2004","unstructured":"Li S, Liang X, Shao Q, Wang G, Huang Y, Wen P, et al. Research hotspots and trends of epigenetic therapy in oncology: a bibliometric analysis from 2004 to 2023. Front Pharmacol. 2004;15:1465954.","journal-title":"Front Pharmacol"},{"issue":"22","key":"3500_CR123","doi-asserted-by":"publisher","first-page":"12453","DOI":"10.1093\/nar\/gkaa1000","volume":"48","author":"A Sgro","year":"2020","unstructured":"Sgro A, Blancafort P. Epigenome engineering: new technologies for precision medicine. Nucleic Acids Res. 2020;48(22):12453\u201382.","journal-title":"Nucleic Acids Res"},{"key":"3500_CR124","doi-asserted-by":"publisher","unstructured":"Dikeocha IJ, Al-Kabsi AM, Miftahussurur M, Alshawsh MA. Pharmacomicrobiomics: influence of gut microbiota on drug and xenobiotic metabolism. FASEB J [Internet]. 2022;36(6):e22350.https:\/\/doi.org\/10.1096\/fj.202101986R.","DOI":"10.1096\/fj.202101986R"},{"key":"3500_CR125","doi-asserted-by":"crossref","unstructured":"Maddu RS, Ghanta AS, Babu DPV. Microbiome-drug interactions: a critical review of pharmacokinetic and pharmacodynamic modulation. Trop J Pharm Life Sci [Internet]. 2025;12(3):26\u201341. https:\/\/informativejournals.com\/journal\/index.php\/tjpls\/article\/view\/185. Accessed 13 Dec 2025.","DOI":"10.61280\/tjpls.v12i3.185"},{"key":"3500_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.685935","volume":"12","author":"RB Young","year":"2021","unstructured":"Young RB, Marcelino VR, Chonwerawong M, Gulliver EL, Forster SC. Key technologies for progressing discovery of microbiome-based medicines. Front Microbiol. 2021;12:685935.","journal-title":"Front Microbiol"},{"issue":"20","key":"3500_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252011259","volume":"25","author":"WK Mousa","year":"2024","unstructured":"Mousa WK, Al Ali A. The gut microbiome advances precision medicine and diagnostics for inflammatory bowel diseases. Int J Mol Sci. 2024;25(20):11259.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3500_CR128","doi-asserted-by":"publisher","DOI":"10.1111\/1751-7915.70041","volume":"17","author":"EL Gulliver","year":"2024","unstructured":"Gulliver EL, Di Simone SK, Chonwerawong M, Forster SC. Unlocking the potential for microbiome\u2010based therapeutics to address the sustainable development goal of good health and wellbeing. Microb Biotechnol. 2024;17(11):e70041.","journal-title":"Microb Biotechnol"},{"key":"3500_CR129","volume":"8","author":"X Fang","year":"2025","unstructured":"Fang X, Wang Y, Wei H, Huang Y. Precision microbiome: a new era of targeted therapy with core probiotics. Research (Wash D C). 2025;8:658.","journal-title":"Research (Wash D C)"},{"key":"3500_CR130","doi-asserted-by":"crossref","unstructured":"Qian Z, Bai W, Li J, Rao X. Gut microbiome-mediated epigenetic modi fi cations in gastric cancer\u202f: a comprehensive multiomics analysis. 2025;(October):1\u201314.","DOI":"10.3389\/fcimb.2025.1585881"},{"issue":"5","key":"3500_CR131","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/bfgp\/elae013","volume":"23","author":"D Acharya","year":"2024","unstructured":"Acharya D, Mukhopadhyay A. A comprehensive review of machine learning techniques for multi-omics data integration: challenges and applications in precision oncology. Brief Funct Genomics. 2024;23(5):549\u201360.","journal-title":"Brief Funct Genomics"},{"issue":"12","key":"3500_CR132","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.7150\/jca.93215","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang S, Wang Z, Wang C, Li C, Wang B. Comparative evaluation of machine learning models for subtyping triple-negative breast cancer: a deep learning-based multi-omics data integration approach. J Cancer. 2024;15(12):3943.","journal-title":"J Cancer"},{"key":"3500_CR133","doi-asserted-by":"crossref","unstructured":"Koh HWL, Fermin D, Vogel C, Choi KP, Ewing RM, Choi H. iOmicsPASS: network-based integration of multiomics data for predictive subnetwork discovery. NPJ Syst Biol Appl [Internet]. 2019 Dec 1 [cited 2025 Oct 22];5(1):22. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6616462\/","DOI":"10.1038\/s41540-019-0099-y"},{"key":"3500_CR134","doi-asserted-by":"crossref","unstructured":"Jagtap S, Pirayre A, Bidard F, Duval L, Malliaros FD. BRANEnet: embedding multilayer networks for omics data integration. BMC Bioinforma [Internet]. 2022;23(1):429. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9575224\/. Accessed 22 Oct 2025.","DOI":"10.1186\/s12859-022-04955-w"},{"key":"3500_CR135","doi-asserted-by":"crossref","unstructured":"Sanches PHG, de Melo NC, Porcari AM, de Carvalho LM. Integrating molecular perspectives: strategies for comprehensive multi-omics integrative data analysis and machine learning applications in transcriptomics, proteomics, and metabolomics. Biol [Internet]. 2024;13(11):848. https:\/\/www.mdpi.com\/2079-7737\/13\/11\/848\/htm. Accessed 22 Oct 2025.","DOI":"10.3390\/biology13110848"},{"key":"3500_CR136","doi-asserted-by":"crossref","unstructured":"Pa\u010d\u00ednkov\u00e1 A, Popovici V. IntOMICS: a bayesian framework for reconstructing regulatory networks using multi-omics data. J Comput Biol. 2023;30(5):569\u201374. https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/cmb.2022.0149.","DOI":"10.1089\/cmb.2022.0149"},{"key":"3500_CR137","doi-asserted-by":"publisher","unstructured":"Zhu B, Zhang Z, Leung SY, Fan X. NetMIM: network-based multi-omics integration with block missingness for biomarker selection and disease outcome prediction. Brief Bioinform [Internet]. 2024;25(5):454. https:\/\/doi.org\/10.1093\/bib\/bbae454.","DOI":"10.1093\/bib\/bbae454"},{"key":"3500_CR138","doi-asserted-by":"crossref","unstructured":"Hu X, Zhang P, Zhang J, Deng L. DeepFusionCDR: employing multi-omics integration and molecule-specific transformers for enhanced prediction of cancer drug responses. IEEE J Biomed Heal Informat [Internet]. 2024;28(10):6248\u201358. https:\/\/ieeexplore.ieee.org\/abstract\/document\/10574297. Accessed 13 Dec 2025.","DOI":"10.1109\/JBHI.2024.3417014"},{"key":"3500_CR139","doi-asserted-by":"publisher","first-page":"1199087","DOI":"10.3389\/fgene.2023.1199087","volume":"14","author":"JS Wekesa","year":"2023","unstructured":"Wekesa JS, Kimwele M. A review of multi-omics data integration through deep learning approaches for disease diagnosis, prognosis, and treatment. Front Genet. 2023;14:1199087.","journal-title":"Front Genet"},{"key":"3500_CR140","doi-asserted-by":"crossref","unstructured":"Selevsek N, Caiment F, Nudischer R, Gmuender H, Agarkova I, Atkinson FL, et al. Network integration and modelling of dynamic drug responses at multi-omics levels. Commun Biol [Internet]. 2020;3(1):573. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7567116\/. Accessed 13 Dec 2025.","DOI":"10.1038\/s42003-020-01302-8"},{"key":"3500_CR141","doi-asserted-by":"crossref","unstructured":"Wu Y, Liu Q, Xie L. Hierarchical multi-omics data integration and modeling predict cell-specific chemical proteomics and drug responses. Cell Rep Methods [Internet]. 2023;3(4):100452. https:\/\/www.cell.com\/action\/showFullText?pii=S2667237523000711. Accessed 13 Dec 2025.","DOI":"10.1016\/j.crmeth.2023.100452"},{"key":"3500_CR142","doi-asserted-by":"publisher","unstructured":"Abid D, Brent MR. NetProphet 3: a machine learning framework for transcription factor network mapping and multi-omics integration. Bioinformatics [Internet]. 2023 Feb 3 [cited 2025 Oct 22];39(2). Available from: https:\/\/doi.org\/10.1093\/bioinformatics\/btad038","DOI":"10.1093\/bioinformatics\/btad038"},{"key":"3500_CR143","doi-asserted-by":"crossref","unstructured":"Li W, Ballard J, Zhao Y, Long Q. Knowledge-guided learning methods for integrative analysis of multi-omics data. Comput Struct Biotechnol J [Internet]. 2024;23:1945\u201350. https:\/\/www.csbj.org\/action\/showFullText?pii=S2001037024001338. Accessed 22 Oct 2025.","DOI":"10.1016\/j.csbj.2024.04.053"},{"key":"3500_CR144","doi-asserted-by":"crossref","unstructured":"Ruiz-Perez D, Lugo-Martinez J, Bourguignon N, Mathee K, Lerner B, Bar-Joseph Z, et al. Dynamic bayesian networks for integrating, multi-omics time series microbiome data. mSystems [Internet]. 2021;6(2):e01105\u201320. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8546994\/. Accessed 22 Oct 2025.","DOI":"10.1128\/msystems.01105-20"},{"key":"3500_CR145","doi-asserted-by":"crossref","unstructured":"Bhattacharyya R, Henderson N, Baladandayuthapani V. BaySyn: bayesian evidence synthesis for multi-system multiomic integration. Pac Symp Biocomput [Internet]. 2023;28(2023):275. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10652956\/. Accessed 22 Oct 2025.","DOI":"10.1142\/9789811270611_0026"},{"key":"3500_CR146","doi-asserted-by":"crossref","unstructured":"Jiang W, Ye W, Tan X, Bao YJ. Network-based multi-omics integrative analysis methods in drug discovery: a systematic review. BioData Min [Internet]. 2025 Dec 1 [cited 2025 Oct 22];18(1):27. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11954193\/","DOI":"10.1186\/s13040-025-00442-z"},{"key":"3500_CR147","doi-asserted-by":"crossref","unstructured":"Tanvir RB, Islam MM, Sobhan M, Luo D, Mondal AM. MOGAT: a multi-omics integration framework using graph attention networks for cancer subtype prediction. Int J Mol Sci [Internet]. 2024;25(5):2788. https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2788\/htm. Accessed 22 Oct 2025.","DOI":"10.3390\/ijms25052788"},{"key":"3500_CR148","doi-asserted-by":"crossref","unstructured":"Molla G, Bitew M. Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives. Biomed [Internet]. 2024;12(12):2750. https:\/\/www.mdpi.com\/2227-9059\/12\/12\/2750\/htm. Accessed 13 Dec 2025.","DOI":"10.3390\/biomedicines12122750"},{"key":"3500_CR149","doi-asserted-by":"publisher","unstructured":"Lin M, Guo J, Gu Z, Tang W, Tao H, You S, et al. Machine learning and multi-omics integration: advancing cardiovascular translational research and clinical practice. J Transl Med [Internet]. 2025;23(1):1\u201317. https:\/\/doi.org\/10.1186\/s12967-025-06425-2.","DOI":"10.1186\/s12967-025-06425-2"},{"key":"3500_CR150","doi-asserted-by":"crossref","unstructured":"Picard M, Scott-Boyer MP, Bodein A, P\u00e9rin O, Droit A. Integration strategies of multi-omics data for machine learning analysis. Comput Struct Biotechnol J [Internet]. 2021;19:3735\u201346. https:\/\/www.csbj.org\/action\/showFullText?pii=S2001037021002683. Accessed 22 Oct 2025.","DOI":"10.1016\/j.csbj.2021.06.030"},{"key":"3500_CR151","doi-asserted-by":"crossref","unstructured":"Qureshi R, Basit SA, Shamsi JA, Fan X, Nawaz M, Yan H, et al. Machine learning based personalized drug response prediction for lung cancer patients. Sci Rep [Internet]. 2022;12(1):1\u201315. https:\/\/www.nature.com\/articles\/s41598-022-23649-0. Accessed 22 Oct 2025.","DOI":"10.1038\/s41598-022-23649-0"},{"key":"3500_CR152","doi-asserted-by":"crossref","unstructured":"Shi Y, Li C, Zhang X, Peng C, Sun P, Zhang Q, et al. D3EGFR: a webserver for deep learning-guided drug sensitivity prediction and drug response information retrieval for EGFR mutation-driven lung cancer. Brief Bioinform [Internet]. 2024;25(3):bbae121. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10981678\/. Accessed 13 Dec 2025.","DOI":"10.1093\/bib\/bbae121"},{"key":"3500_CR153","doi-asserted-by":"publisher","unstructured":"Park H, Yamaguchi R, Imoto S, Miyano S. Xprediction: Explainable EGFR-TKIs response prediction based on drug sensitivity specific gene networks. PLoS One [Internet]. 2022 May 1 [cited 2025 Dec 13];17(5):e0261630. Available from: https:\/\/journals.plos.org\/plosone\/article?id=https:\/\/doi.org\/10.1371\/journal.pone.0261630","DOI":"10.1371\/journal.pone.0261630"},{"key":"3500_CR154","doi-asserted-by":"publisher","unstructured":"Dong Q, Wu J, Zhang H, Chen X, Xu X, Chen J, et al. Deciphering immunometabolic landscape in rheumatoid arthritis: integrative multiomics, explainable machine learning and experimental validation. J Inflamm Res [Internet]. 2025;18:637\u201352. https:\/\/doi.org\/10.2147\/JIR.S503118.","DOI":"10.2147\/JIR.S503118"},{"key":"3500_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1409555","volume":"15","author":"Y Shi","year":"2024","unstructured":"Shi Y, Zhou M, Chang C, Jiang P, Wei K, Zhao J, et al. Advancing precision rheumatology: applications of machine learning for rheumatoid arthritis management. Front Immunol. 2024;15:1409555.","journal-title":"Front Immunol"},{"key":"3500_CR156","doi-asserted-by":"crossref","unstructured":"Chen J, Li S, Zhu J, Su W, Jian C, Zhang J, et al. Multi-omics profiling reveals potential alterations in rheumatoid arthritis with different disease activity levels. Arthritis Res Ther [Internet]. 2023;25(1):74. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10155393\/. Accessed 13 Dec 2025.","DOI":"10.1186\/s13075-023-03049-z"},{"key":"3500_CR157","doi-asserted-by":"crossref","unstructured":"Huang Y, Yue S, Qiao J, Dong Y, Liu Y, Zhang M, et al. Identification of diagnostic genes and drug prediction in metabolic syndrome-associated rheumatoid arthritis by integrated bioinformatics analysis, machine learning, and molecular docking. Front Immunol [Internet]. 2024;15:1431452. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11320606\/. Accessed 13 Dec 2025.","DOI":"10.3389\/fimmu.2024.1431452"},{"key":"3500_CR158","doi-asserted-by":"publisher","unstructured":"Mukherjee A, Abraham S, Singh A, Balaji S, Mukunthan KS. From data to cure: a comprehensive exploration of multi-omics data analysis for targeted therapies. Mol Biotechnol [Internet]. 2024;67(4):1269\u201389. https:\/\/doi.org\/10.1007\/s12033-024-01133-6.","DOI":"10.1007\/s12033-024-01133-6"},{"key":"3500_CR159","doi-asserted-by":"publisher","unstructured":"Keshri V, Belurappa J. Multi-omics applications in drug discovery and development. Multi-Omics Biomed Sci Environ Sustain Appl Recent Adv [Internet]. 2025;143\u201358. https:\/\/doi.org\/10.1007\/978-981-96-7067-3_5.","DOI":"10.1007\/978-981-96-7067-3_5"},{"key":"3500_CR160","doi-asserted-by":"crossref","unstructured":"Du P, Fan R, Zhang N, Wu C, Zhang Y. Advances in integrated multi-omics analysis for drug-target identification. Biomol [Internet]. 2024;14(6):692. https:\/\/www.mdpi.com\/2218-273X\/14\/6\/692\/htm. Accessed 22 Oct 2025.","DOI":"10.3390\/biom14060692"},{"key":"3500_CR161","doi-asserted-by":"crossref","unstructured":"Yang H, Gan L, Chen R, Li D, Zhang J, Wang Z. From multi-omics data to the cancer druggable gene discovery: a novel machine learning-based approach. bioRxiv [Internet]. 2022. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.07.24.501277v1. Accessed 22 Oct 2025.","DOI":"10.1101\/2022.07.24.501277"},{"key":"3500_CR162","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Cort\u00e9s A, Cabrera-Andrade A, Echeverr\u00eda-Garc\u00e9s G, Echeverr\u00eda-Espinoza P, Pineda-Alb\u00e1n M, Elsitdie N, et al. Unraveling druggable cancer-driving proteins and targeted drugs using artificial intelligence and multi-omics analyses. Sci Rep [Internet]. 2024;14(1):1\u201322. https:\/\/www.nature.com\/articles\/s41598-024-68565-7. Accessed 22 Oct 2025.","DOI":"10.1038\/s41598-024-68565-7"},{"key":"3500_CR163","doi-asserted-by":"crossref","unstructured":"Lessard S, Chao M, Reis K, Beauvais M, Rajpal DK, Sloane J, et al. Leveraging large-scale multi-omics evidences to identify therapeutic targets from genome-wide association studies. BMC Genomics [Internet]. 2024;25(1):1111. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11577829\/. Accessed 22 Oct 2025.","DOI":"10.1186\/s12864-024-10971-2"},{"key":"3500_CR164","doi-asserted-by":"crossref","unstructured":"Deng EZ, Marino GB, Clarke DJB, Diamant I, Resnick AC, Ma W, et al. Multiomics2Targets identifies targets from cancer cohorts profiled with transcriptomics, proteomics, and phosphoproteomics. Cell Repo Methods [Internet]. 2024;4(8):100839. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11384097\/. Accessed 22 Oct 2025.","DOI":"10.1016\/j.crmeth.2024.100839"},{"key":"3500_CR165","doi-asserted-by":"crossref","unstructured":"Hussein R, Abou-Shanab AM, Badr E. A multi-omics approach for biomarker discovery in neuroblastoma: a network-based framework. npj Syst Biol Appl [Internet]. 2024;10(1):1\u201314. https:\/\/www.nature.com\/articles\/s41540-024-00371-3. Accessed 22 Oct 2025.","DOI":"10.1038\/s41540-024-00371-3"},{"key":"3500_CR166","doi-asserted-by":"crossref","unstructured":"Wang H, Xie J, Tian Z, Allen-Gipson DS, Tang H. Editorial: Multi-omics application in exploring potential biomarkers targeting resistance of anti-cancer drugs. Front Pharmacol [Internet]. 2025;16:1594064. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12044877\/. Accessed 22 Oct 2025.","DOI":"10.3389\/fphar.2025.1594064"},{"issue":"6_Supplement","key":"3500_CR167","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1158\/1538-7445.AM2024-2856","volume":"84","author":"AFS Peres","year":"2024","unstructured":"Peres AFS, Cardoso IIV, Galvao JMS, Vieira AGS, Rosa MN, Tosi IC, et al. Abstract 2856: multi-omics approaches for biomarker discovery and target therapy in pediatric germ cell tumors. Cancer Res. 2024;84(6_Supplement):2856\u20132856.","journal-title":"Cancer Res"},{"key":"3500_CR168","doi-asserted-by":"crossref","unstructured":"Srivastava R. Advancing precision oncology with AI-powered genomic analysis. Front Pharmacol [Internet]. 2025;16:1591696. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12075946\/. Accessed 22 Oct 2025.","DOI":"10.3389\/fphar.2025.1591696"},{"key":"3500_CR169","doi-asserted-by":"publisher","unstructured":"Alaseem AM, Alasiri G, Marianesan AB, Singh TG, Alam P, Fareed M, et al. Target-specific potency and drug-ability profile of flavonoids against lung cancer: an integrative multi-omics approach for lead identification. Drug Dev Res [Internet]. 2025;86(5):e70131. https:\/\/doi.org\/10.1002\/ddr.70131.","DOI":"10.1002\/ddr.70131"},{"key":"3500_CR170","doi-asserted-by":"publisher","unstructured":"Mohammadzadeh-Vardin T, Ghareyazi A, Gharizadeh A, Abbasi K, Rabiee HR. DeepDRA: drug repurposing using multi-omics data integration with autoencoders. PLoS One [Internet]. 2024;19(7):e0307649. https:\/\/doi.org\/10.1371\/journal.pone.0307649","DOI":"10.1371\/journal.pone.0307649"},{"key":"3500_CR171","doi-asserted-by":"publisher","unstructured":"Wang L, Wang X, Wang T, Zhuang Y, Wang G. Multi-omics analysis defines 5-fluorouracil drug resistance in 3D HeLa carcinoma cell model. Authorea Prepr [Internet]. 2024. https:\/\/doi.org\/10.22541\/au.170667161.10681869\/v1","DOI":"10.22541\/au.170667161.10681869\/v1"},{"key":"3500_CR172","doi-asserted-by":"crossref","unstructured":"Yu XN, Wu HT, Wu BX, Zhi SF, Lan YZ, Chen WJ, et al. Advances and challenges in drug repurposing in precision therapeutics of colorectal cancer. World J Gastrointest Oncol [Internet]. 2025;17(7):107681. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12278253\/. Accessed 13 Dec 2025.","DOI":"10.4251\/wjgo.v17.i7.107681"},{"key":"3500_CR173","doi-asserted-by":"crossref","unstructured":"Chai S, Cui J, Sun Y, Wang X, Cai C. Exploring novel therapeutic targets in breast cancer via comprehensive omics profiling and experimental verification. Biology (Basel) [Internet]. 2025;14(4):405. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12025194\/. Accessed 22 Oct 2025.","DOI":"10.3390\/biology14040405"},{"key":"3500_CR174","doi-asserted-by":"publisher","unstructured":"Galkin F, Naumov V, Pushkov S, Sidorenko D, Urban A, Zagirova D, et al. Precious3GPT: multimodal multi-species multi-omics multi-tissue transformer for aging research and drug discovery. bioRxiv [Internet]. https:\/\/doi.org\/10.1101\/2024.07.25.605062v1.","DOI":"10.1101\/2024.07.25.605062v1"},{"key":"3500_CR175","doi-asserted-by":"publisher","unstructured":"Jose A, Kulkarni P, Thilakan J, Munisamy M, Malhotra AG, Singh J, et al. Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine. Mol Cancer 2024 231 [Internet]. 2024;23(1):50. https:\/\/doi.org\/10.1186\/s12943-023-01916-6.","DOI":"10.1186\/s12943-023-01916-6"},{"key":"3500_CR176","doi-asserted-by":"crossref","unstructured":"Zhu Y, Tang S, Yuan Q, Fu J, He J, Liu Z, et al. Integrated characterization of hepatobiliary tumor organoids provides a potential landscape of pharmacogenomic interactions. Cell Reports Med [Internet]. 2024;5(2):101375. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10897507\/. Accessed 13 Dec 2025.","DOI":"10.1016\/j.xcrm.2023.101375"},{"issue":"1","key":"3500_CR177","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.30574\/ijsra.2023.8.1.0189","volume":"8","author":"H Ali","year":"2023","unstructured":"Ali H. Artificial intelligence in multi-omics data integration: advancing precision medicine, biomarker discovery and genomic-driven disease interventions. Int J Sci Res Arch. 2023;8(1):1012\u201330.","journal-title":"Int J Sci Res Arch"},{"key":"3500_CR178","unstructured":"Liu F, Beck S, Yang L, Luo H, Zhang K. Advancing AI for multi-omics and clinical data integration in basic and translational cancer research. Nat Rev Cancer 2026 [Internet]. 2026;1\u201316. https:\/\/www.nature.com\/articles\/s41568-026-00922-2. Accessed 3 Jun 2026."},{"key":"3500_CR179","unstructured":"Krug K, Jaehnig EJ, Satpathy S, Blumenberg L, Karpova A, Anurag M, et al. Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. Cell [Internet]. 2020;183(5):1436\u20131456.e31. https:\/\/www.cell.com\/action\/showFullText?pii=S0092867420314008. Accessed 22 Oct 2025."},{"key":"3500_CR180","doi-asserted-by":"crossref","unstructured":"Soltis AR, Bateman NW, Liu J, Nguyen T, Franks TJ, Zhang X, et al. Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways. Cell Rep Med [Internet]. 2022;3(11):100819. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666379122003780?via%3Dihub. Accessed 22 Oct 2025.","DOI":"10.1016\/j.xcrm.2022.100819"},{"key":"3500_CR181","doi-asserted-by":"crossref","unstructured":"Hira MT, Razzaque MA, Angione C, Scrivens J, Sawan S, Sarkar M. Integrated multi-omics analysis of ovarian cancer using variational autoencoders. Sci Rep [Internet]. 2021;11(1):1\u201316. https:\/\/www.nature.com\/articles\/s41598-021-85285-4. Accessed 22 Oct 2025.","DOI":"10.1038\/s41598-021-85285-4"},{"key":"3500_CR182","doi-asserted-by":"publisher","unstructured":"Zheng K, Hai Y, Xi Y, Zhang Y, Liu Z, Chen W, et al. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance. J Transl Med [Internet]. 2023;21(1):1\u201319. https:\/\/doi.org\/10.1186\/s12967-023-04683-6.","DOI":"10.1186\/s12967-023-04683-6"},{"key":"3500_CR183","doi-asserted-by":"crossref","unstructured":"Ding Y, Xu Z, Hu W, Deng P, Ma M, Wu J. Comprehensive multi-omics and machine learning framework for glioma subtyping and precision therapeutics. Sci Rep [Internet]. 2025;15(1):1\u201317. https:\/\/www.nature.com\/articles\/s41598-025-09742-0. Accessed 22 Oct 2025.","DOI":"10.1038\/s41598-025-09742-0"},{"key":"3500_CR184","doi-asserted-by":"publisher","unstructured":"Codrich M, Dalla E, Mio C, Antoniali G, Malfatti MC, Marzinotto S, et al. Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN. J Exp Clin Cancer Res [Internet]. 2021;40(1):1\u201317. https:\/\/doi.org\/10.1186\/s13046-021-01986-8.","DOI":"10.1186\/s13046-021-01986-8"},{"key":"3500_CR185","doi-asserted-by":"publisher","unstructured":"Wei L, Niraula D, Gates EDH, Fu J, Luo Y, Nyflot MJ, et al. Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration. Br J Radiol [Internet]. 2023;96(1150). https:\/\/doi.org\/10.1259\/bjr.20230211.","DOI":"10.1259\/bjr.20230211"},{"key":"3500_CR186","doi-asserted-by":"crossref","unstructured":"Yadav S, Mondal J, Saha M. Systems biology approaches for multi omics integration using artificial intelligence. Acad Biol. 2026;4(1). https:\/\/www.academia.edu\/2837-4010\/4\/1\/10.20935\/AcadBiol8077.","DOI":"10.20935\/AcadBiol8077"},{"key":"3500_CR187","doi-asserted-by":"crossref","unstructured":"Yates J, Van Allen EM. New horizons at the interface of artificial intelligence and translational cancer research. Cancer Cell [Internet]. 2025;43(4):708\u201327. https:\/\/www.cell.com\/action\/showFullText?pii=S1535610825001199. Accessed 3 Jun 2026.","DOI":"10.1016\/j.ccell.2025.03.018"},{"key":"3500_CR188","doi-asserted-by":"publisher","unstructured":"Menyh\u00e1rt O, Gy\u0151rffy B. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J [Internet]. 2021;19:949\u201360. https:\/\/doi.org\/10.1016\/j.csbj.2021.01.009?download=true.","DOI":"10.1016\/j.csbj.2021.01.009?download=true"},{"key":"3500_CR189","doi-asserted-by":"publisher","unstructured":"Wolde T, Bhardwaj V, Pandey V. Current bioinformatics tools in precision oncology. MedComm [Internet]. 2025;6(7):e70243. https:\/\/doi.org\/10.1002\/mco2.70243.","DOI":"10.1002\/mco2.70243"},{"key":"3500_CR190","doi-asserted-by":"publisher","unstructured":"Singer J, Irmisch A, Ruscheweyh HJ, Singer F, Toussaint NC, Levesque MP, et al. Bioinformatics for precision oncology. Brief Bioinform [Internet]. 2019;20(3):778\u201388. https:\/\/doi.org\/10.1093\/bib\/bbx143.","DOI":"10.1093\/bib\/bbx143"},{"key":"3500_CR191","doi-asserted-by":"publisher","unstructured":"Tsimberidou AM, Ringborg U, Schilsky RL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ B [Internet]. 2013;(33):118\u201325. https:\/\/doi.org\/10.14694\/EdBook_AM.2013.33.118.","DOI":"10.14694\/EdBook_AM.2013.33.118"},{"key":"3500_CR192","unstructured":"Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar S V., Krug K, et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell [Internet]. 2020;182(1):200\u2013225.e35. https:\/\/www.cell.com\/action\/showFullText?pii=S0092867420307443. Accessed 3 Jun 2026."},{"key":"3500_CR193","doi-asserted-by":"publisher","unstructured":"Kickingereder P, Bonekamp D, Nowosielski M, Kratz A, Sill M, Burth S, et al. Radiogenomics of glioblastoma: machine learning\u2013based classification of molecular characteristics by using multiparametric and multiregional MR imaging features.  Radiology [Internet]. 2016;281(3):907\u201318. https:\/\/doi.org\/10.1148\/radiol.2016161382.","DOI":"10.1148\/radiol.2016161382"},{"key":"3500_CR194","doi-asserted-by":"publisher","unstructured":"L\u00e4hnemann D, K\u00f6ster J, Szczurek E, McCarthy DJ, Hicks SC, Robinson MD, et al. Eleven grand challenges in single-cell data science. Genome Biol [Internet]. 2020;21(1):31. https:\/\/doi.org\/10.1186\/s13059-020-1926-6.","DOI":"10.1186\/s13059-020-1926-6"},{"key":"3500_CR195","doi-asserted-by":"crossref","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of\u00a0liquid biopsies in genomics-driven oncology. Nat Rev Genet 2018 202 [Internet]. 2018;20(2):71\u201388. https:\/\/www.nature.com\/articles\/s41576-018-0071-5. Accessed 3 Jun 2026.","DOI":"10.1038\/s41576-018-0071-5"},{"key":"3500_CR196","doi-asserted-by":"crossref","unstructured":"Arora D, Jahangir M, Wadhwa K, Kriplani P, Taruna, Mishra N, et al. Challenges and limitations of liquid biopsy in precision oncology. Liq biopsy Cancer Manag Integr Diagnostics Clin Appl [Internet]. 2026;357\u201372. https:\/\/www.sciencedirect.com\/science\/chapter\/edited-volume\/abs\/pii\/B9780443274961000038. Accessed 3 Jun 2026.","DOI":"10.1016\/B978-0-443-27496-1.00003-8"},{"key":"3500_CR197","doi-asserted-by":"crossref","unstructured":"Coppola CA, De Summa S, Matera G, Pilato B, Traversa D, Tommasi S. Liquid biopsy: the challenges of a revolutionary approach in oncology. Int J Mol Sci [Internet]. 2025;26(11):5013. Available from: https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5013\/htm. Accessed 3 Jun 2026.","DOI":"10.3390\/ijms26115013"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03500-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03500-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03500-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:02:50Z","timestamp":1788253370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03500-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":197,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3500"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03500-9","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"261"}}